胆管内乳头状粘液性肿瘤一例报道
Intraductal Papillary Mucinous Neoplasm of the Bile Duct: A Case Report
DOI: 10.12677/acm.2025.1592518, PDF, HTML, XML,   
作者: 王建勇:赣南医科大学第一临床医学院,江西 赣州;何 晓*:赣南医科大学第一附属医院肝胆胰外科,江西 赣州
关键词: 胆管肿瘤胆管内乳头状粘液性肿瘤诊断手术治疗Bile Duct Tumor Intraductal Papillary Mucinous Neoplasm of the Bile Duct Diagnosis Surgery Treatment
摘要: 报道1例51岁女性患者,因“外院体检彩超检查发现肝内占位性病变1天”就诊于赣南医科大学第一附属医院,经右半肝切除术,术后病理证实为:胆管内乳头状粘液性肿瘤,随访1年,未发生复发及转移。
Abstract: We report the case of a 51-year-old woman who was referred to The First Affiliated Hospital of Gannan Medical University after an abdominal ultrasound during a routine health examination at an external facility revealed a hepatic mass. The patient underwent a right hemihepatectomy, and postoperative pathology confirmed the diagnosis of intraductal papillary mucinous neoplasm (IPMN) of the bile duct. At the one-year follow-up, there was no evidence of recurrence or metastasis.
文章引用:王建勇, 何晓. 胆管内乳头状粘液性肿瘤一例报道[J]. 临床医学进展, 2025, 15(9): 496-503. https://doi.org/10.12677/acm.2025.1592518

1. 引言

胆管内乳头状黏液性肿瘤(Biliary tract intraductal papillary mucinous neoplasm, BT-IPMN)是一种源自胆道上皮的罕见肿瘤,BT-IPMN的主要病因包括肝内胆管结石和华支睾吸虫感染[1]。其发病机制尚不明确。常见临床症状为腹痛和黄疸,由大量分泌的黏液引起胆管梗阻。早期明确诊断较为困难,主要诊断方式为CT或MRI检查,影像学特征为胆管局灶性或弥漫性扩张和胆管内肿块。首选治疗方式为手术治疗。由于该病发病率低,临床医生对其认识可能不足,难以明确诊断,因此此例病例报道有助于增加临床医生对该疾病的认知,特别是在影像学表现和病理特征方面。本文回顾性分析我院1例BT-IPMN患者的临床资料,并结合文献进行讨论。

2. 临床资料

Figure 1. Diffuse mild cystic dilation of the intrahepatic and extrahepatic bile ducts

1. 肝内外胆管广泛轻度囊状扩张

Figure 2. Diffuse mild cystic dilation of the intrahepatic and extrahepatic bile ducts

2. 肝内外胆管广泛轻度囊状扩张

Figure 3. Pathology (HE × 100): Intraductal papillary mucinous neoplasm of the bile duct with associated invasive carcinoma (moderately differentiated adenocarcinoma)

3. 病理(HE × 100):胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌)

Figure 4. Pathology (HE × 100): Intraductal papillary mucinous neoplasm of the bile duct with associated invasive carcinoma (moderately differentiated adenocarcinoma)

4. 病理(HE × 100):胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌)

患者女,51岁,因“外院体检彩超检查发现肝内占位性病变1天入院”。8月前因胆囊结石于当地医院行“胆囊切除术”。无乙肝、丙肝病史,无饮酒史。患者于1天前在当地医院体检,彩超检查发现肝内占位性病变,无反酸、嗳气,无恶心、呕吐、呕血,无腹痛、腹胀、腹泻,无便血、便秘,无寒战、发热等不适。为进一步诊治遂来我院就诊,门诊拟“肝内占位性病变”收住我科。体格检查:全身皮肤黏膜色泽正常,未见皮疹,无皮下结节、瘢痕,未见皮下出血点及瘀斑,未见肝掌,未见蜘蛛痣。腹部平坦,软,无压痛及反跳痛,未触及腹部包块,肝脏肋下2 cm触及,质硬,边界清,有触痛感,脾脏肋下未触及,移动性浊音阴性,肠鸣音正常,双侧肾区无叩痛。2024-02-01上腹部(肝脏,胆,脾,胰) CT平扫 + 增强(图1图2):1) 肝右叶巨大占位,考虑恶性肿瘤,HCC可能性大;肝右静脉显影不清;2) 肝硬化征象;肝内外胆管轻度扩张;肝周少量积液;3) 胆囊术后缺如;4) 右肺下叶实性小结节,随诊;5) 主动脉硬化;6) 甲状腺稍增粗并密度减低,请结合超声及甲状腺功能检查。2024-02-01肝功能:丙氨酸氨基转移酶(速率法) 14 U/ml天门冬氨酸氨基转移酶(速率法) 20 U/ml。2024-02-01肿瘤五项:AFP2.63 ng/ml,CEA癌胚抗原(电化学发光) 238 ng/ml,肿瘤相关抗原199 (电化学发光) 46.7 U/ml,CA125 15.6 ng/ml CA153 21.3 ng/ml,乙肝、丙肝阴性,排除手术禁忌症,于2024年2月4日在全麻下行“右半肝切除术+肠粘连松解术”,手术过程顺利。术后恢复佳,病理提示(右半肝)考虑胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌),待免疫组化检查协助诊断。(图3图4)术后免疫组化:(右半肝)胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌),结合形态及免疫组化检查,考虑胰胆管型。2401861-A12#:CK19(+)、MUC5AC(部分+)、CK7(部分+)、CEA(+)、CK20(−)、CDX-2(−)、MUC2(+)、MUC6(−)、Villin(+)、Pax-8(−)、Ki-67(热点区约40%,+)、Hepatocyte(部分+)、GS-6(−)。(图5图6)术后9天出院。最终诊断:胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌)。出院后1年随访,患者存活。

Figure 5. Immunohistochemistry: MUC5AC(+) The diagnosis was intraductal papillary mucinous neoplasm of the bile duct with associated invasive carcinoma (moderately differentiated adenocarcinoma). Based on the histological features and immunohistochemical profile, the pancreatobiliary subtype was considered

5. 免疫组化:MUC5AC(+)胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌),结合形态及免疫组化检查,考虑胰胆管型

Figure 6. Immunohistochemistry: CK19(+) The diagnosis was intraductal papillary mucinous neoplasm of the bile duct with associated invasive carcinoma (moderately differentiated adenocarcinoma). Based on the histological features and immunohistochemical profile, the pancreatobiliary subtype was considered

6. 免疫组化:CK19(+)胆管内乳头状黏液性肿瘤伴浸润性癌(中分化腺癌),结合形态及免疫组化检查,考虑胰胆管型

3. 讨论

胆管内乳头状黏液性肿瘤(Biliary tract intraductal papillary mucinous neoplasm, BT-IPMN)是一种源自胆道上皮的罕见肿瘤,BT-IPMN的主要病因包括肝内胆管结石和华支睾吸虫感染。BT-IPMN也与原发性硬化性胆管炎及先天性胆道疾病相关[1]。然而,BT-IPMN的确切发病机制仍不清楚。2010年世界卫生组织将胆管内乳头状肿瘤(Intraductal papillary neoplasm of the bile tract, IPNB)正式采用为一类单独的胆道肿瘤类型[2]。依据IPNB的细胞结构分级,提出了IPNB分型,IPNB根据导管内乳头成分的显微结构分为1型和2型。1型IPNB (BT-IPMN)是典型类型,具有结构良好的乳头状结构、胆管囊性扩张及大量黏液分泌。由于其病理特征与IPMN相似,1型IPNB被认为是其在胆道系统的对应形式。2型IPNB,也被称为乳头状胆管癌。其特征尚未完全明确。其乳头状结构较为复杂,表现出不规则分支、筛状腺体以及导管内成团坏死,且很少分泌大量黏液分泌[3]。最近,提出了一种证明形态学和病理学特征之间相关性的形态学分类。可能通过术前预测其亚型来补充病理分类。将IPNB分为三种形态类型——分支、主导管和混合。该分类与术后预后具有明显的相关性,可能有助于指导针对IPNB患者每种形态类型量身定制的手术策略[4]。在本病例中,患者右半肝书页状切开后,可见切面呈胶冻样,且可见黏液分泌,患者术后病理分型为1型。

IPNB主要特征是腔内生长的上皮肿瘤,伴有细小的纤维血管柄。受累胆管因导管内肿瘤肿块和粘液分泌过多而出现扩张,临床上可通过影像学检查和内窥镜检查识别。IPNB被认为是胆道癌的浸润前前体。而从前体进展为浸润性癌很可能是胆道癌的一个主要过程[5]。胆管周围毛细血管丛(The peribiliary capillary plexus, PCP)的免疫染色可能是评估前体恶性进展的新病理工具。IPNB的茎或基质中PCP样毛细血管的丢失可能与IPNB的恶性进展有关[6]。约一半的IPNB病例均劫持了PCP作为其支持血管(血管共同选择),腔内肿瘤成分与稀疏的毛细血管相关,几乎没有纤维化[7]。IPNB根据免疫组织化学粘蛋白核心蛋白的形态和各种表达分为四种表型:胰胆、肠、胃和嗜酸细胞。其中,最常见的亚型是胰胆型,其次是肠、胃和嗜酸细胞型。IPNB的免疫组织化学研究通常基于粘蛋白核心蛋白,包括粘蛋白MUC1、MUC2、MUC5AC和MUC6,以及许多肿瘤相关分子,包括p53、p16、SMAD4、β-catenin、KRAS、GNAS、CDX2、细胞角蛋白7、和细胞角蛋白20。而晚期病变(高度异型增生或伴有相关浸润性癌的IPNB)和MUC1的高水平表达与不良结果相关[1]。在我们的病例中,结合病理形态及免疫组化检查,考虑胰胆管型。而未来在胆道肿瘤序贯致癌机制、病理学–基因组相关性和潜在治疗靶点方面或许可以进行更多相关研究。

IPNB作为胆管癌的癌前病变,多发生在老年男性患者中。IPNB的常见症状是腹痛和黄疸。实验室检查可能显示胆红素和转氨酶升高。CA19-9,癌胚抗原CEA对IPNB具有一定诊断价值,但特异度和敏感度较差,影像学检查为其主要的检查方法,影像学特征为胆管扩张[8]。当超声检查发现导管内肿块或囊性实性肿块伴胆管扩张,或显著胆管扩张无导管内肿块时,应考虑IPNB,但通常不建议使用超声成像来确认诊断,因为超声成像的敏感性低、准确性低。此外,在超声图像中很难识别小病灶,导管内肿块有时会与淤泥、非阴影结石或血凝块混淆[9]。而超声造影剂增强可用于区分导管内或壁内肿瘤与胆道系统中的淤泥、脓液和凝块。导管内乳头状黏膜变化表现为高回声带状增厚,超声造影上显示有高增强。腔内重要淋巴结在动脉期过度增强,然后显示清除[10]。故而推荐常规行CT或MRI检查。CT和MRI在疑似胆道肿瘤患者诊断IPNB中均具有临床意义。IPNB的影像学表现因胆管内病变的位置、大小和数量而异。通常,IPNB表现为胆管局灶性或弥漫性扩张和胆管内肿块[11]。PET-CT联合CA19-9水平升高的检测方案,在预测伴有高级别瘤变或癌变的胆管内乳头状肿瘤时,显示出91.8%的敏感性和61.9%的特异性[12]。MRI在评估IPNB方面比CT更准确和可靠。术前MRI不仅在区分IPNB亚型方面具有临床价值,而且在提示肿瘤侵袭性方面具有临床价值。磁共振胰胆管造影(Magnetic Resonance Cholangiopancreatography, MRCP)可以直观地显示胆管系统的扩张及其梗阻部位,并确定病变是否与其相连。MRCP有助于区分IPNB合并相关浸润性癌和IPNB合并上皮内瘤变[13]。近年来,随着内镜技术的不断发展和应用,经内镜逆行胰胆管造影(Endoscopic Retrograde Cholangiopancreatography, ERCP)也被广泛应用于胆道系统疾病的诊断与治疗,ERCP可以直视观察乳头处的胶冻样黏液,为提供诊断的重要依据,而联合胆管镜检查,可以发现肝内导管的细小病变,并且可以用于有针对性的活检和直接检查疾病的范围,以便为手术提供精确的解剖信息[14]。本例患者术前进行了增强CT检查,但仅发现肝内外胆管广泛轻度囊状扩张,由于临床上此类病例非常罕见,并未在术前明确诊断,而误诊为肝细胞癌。回顾此病例,CT表现为导管内肿块及囊性扩张,符合IPNB的影像学表现,应考虑诊断为IPNB。因此掌握该病的特征性影像学表现对临床诊断具有重要意义,需引起高度重视。

IPNB的主要治疗方法是手术治疗,对于放射学怀疑的IPNB,建议早期手术。因为它通常是侵袭性的。胰胆IPNB表达MUC1的比例显著更高(86.4%),与其他IPNB亚型相比,胰胆亚型浸润性癌的发生率(72.7%)显著高于胃型(26.7%)和肠道(32.6%)亚型。肝内IPNB的总生存期优于肝外IPNB。IPNB切除术后绝对生存率的估计值为1年时96%,3年时为79%,5年时为65% [15]。IPNB最佳手术策略的确定取决于病变的部位和范围。位于肝内胆管的肿瘤应进行肝切除术,而位于肝外胆管的肿瘤应进行胰十二指肠切除术或胆管切除术。R0切除比R1切除具有更好的中位生存期。肿瘤完全切除与良好的生存率相关,即使在恶性IPNB患者中也是如此[16]。此外,由于弥漫型IPNB的特点是术前CT图像上多个肿块的比例显著更高,应考虑扩大手术范围,以获得阴性切缘[17]。淋巴结转移在IPNB中较少见。对于是否行区域淋巴结清扫,尚未有定论。但对于恶性IPNB,淋巴结转移和切除完成度与患者生存率显著相关。建议对怀疑为恶性IPNB患者行规范的淋巴结清扫[18]。对于沿胆管粘膜浅表扩散或手术切缘阳性的患者,肝移植可能被认为是唯一的确定性治疗方法。但淋巴结阳性或严重肿瘤浸润或相关严重合并症的患者不符合肝移植条件[19]。近年来关于IPNB的姑息性治疗有所进展,但应用并不广泛,疗效缺乏数据支持。在非手术健康的患者中,已有一些姑息性治疗,如放化疗、经皮经肝胆道引流、胆道支架置入术和内镜入路(包括胆管镜电凝、氩等离子体凝固术、射频消融术和光动力疗法)。迄今为止,大多数以前的研究是单个患者的病例报告或缺乏关于放化疗方案或时间表的详细数据的文章。有研究表明,施用立体定向放射治疗(Stereotactic body radiation therapy, SBRT)治疗不能手术的粘蛋白分泌型IPNB可以抑制粘蛋白分泌并促进黄疸和胆管炎的改善,并可能防止未来发展为胆管癌[20]。内窥镜超声引导下胆总管十二指肠造口术可以创建了一条通往胆管的通路,插入一个管腔并置金属支架,对胆管中的肿瘤进行氩浆凝固,预防胆管炎复发[21]。此外,胆管镜引导下激光消融具有良好的消融效果,可能是IPNB的一种有前途的治疗方式[22]。对于局限性病灶,胆管镜引导下的光动力疗法靶向干预在技术上是可行的,有利于实现人类局限性病灶的精确治疗[23]。因此,对于不适合手术的患者,内镜下射频消融术(Endoscopic Radiofrequency Ablation, ERFA)、氩等离子体凝固(Argon Plasma Coagulation, APC)和光动力疗法(Photodynamic Therapy, PDT)可用于局部治疗。在此例病例中,予以患者行“右半肝切除术”,虽未在术前明确诊断,但术后获得了阴性切缘,且患者术后1年未见复发转移。因此对于术前评估疑似为IPNB的患者,应尽快进行手术治疗并完成R0切除。

总之,IPNB是一种罕见的胆管肿瘤,难以诊断。术前诊断主要依靠影像学,常见的诊断方法包括CT和MRI,然而由于IPNB的多灶性特点,常无法准确判断肿瘤的病变程度,确诊仍需术后病理。因此术前评估疑似为IPNB且无手术禁忌证的患者,需要在仔细的术前评估的基础上制定准确的计划,手术是其主要的治疗方式。

声 明

该病例报道已获得病人的知情同意。

NOTES

*通讯作者。

参考文献

[1] Kim, J.R., Jang, K. and Jang, J. (2023) Intraductal Papillary Neoplasm of the Bile Duct: Review of Updated Clinicopathological and Imaging Characteristics. British Journal of Surgery, 110, 1229-1240.
https://doi.org/10.1093/bjs/znad202
[2] Bosman, F.T., Carneiro, F., Hruban, R.H., et al. (2010) WHO Classification of Tumours of the Digestive System. IARC Publications.
[3] Zen, Y. and Akita, M. (2023) Neoplastic Progression in Intraductal Papillary Neoplasm of the Bile Duct. Archives of Pathology & Laboratory Medicine, 148, 989-996.
https://doi.org/10.5858/arpa.2022-0407-ra
[4] Noguchi, D., Kuriyama, N., Kozuka, Y., Komatubara, H., Sakamoto, T., Ito, T., et al. (2025) A Recent Update on the Morphological Classification of Intraductal Papillary Neoplasm of the Bile Duct: Correlation with Postoperative Prognosis and Pathological Features. PLOS One, 20, e0325081.
https://doi.org/10.1371/journal.pone.0325081
[5] Nakanuma, Y., Kakuda, Y., Sugino, T., Sato, Y. and Fukumura, Y. (2022) Pathologies of Precursor Lesions of Biliary Tract Carcinoma. Cancers, 14, Article 5358.
https://doi.org/10.3390/cancers14215358
[6] Nakanuma, Y., Kakuda, Y., Canh, H.N., Sasaki, M., Harada, K. and Sugino, T. (2024) Pathologic Characterization of Precursors and Cholangiocarcinoma Referring to Peribiliary Capillary Plexus: A New Pathologic Approach to Bile Duct Neoplasm. Virchows Archiv, 485, 257-268.
https://doi.org/10.1007/s00428-024-03859-9
[7] Nakanuma, Y., Li, Z., Sato, Y., Sasaki, M., Harada, K., Kakuda, Y., et al. (2024) A Pathological Assessment of the Microvasculature of Biliary Tract Neoplasms Referring to Pre-Existing Blood Vessels and Vessel Co-Option. Cancers, 16, Article 3869.
https://doi.org/10.3390/cancers16223869
[8] Fu, C., Jin, H., Wang, Y. and Xu, H. (2024) Clinicopathological Features and Surgical Treatments of Intraductal Papillary Neoplasm of the Bile Duct: A Case Report and Literature Review. Frontiers in Medicine, 11, Article 1443599.
https://doi.org/10.3389/fmed.2024.1443599
[9] Liu, L., Xu, H., Zheng, S., Sun, L., Guo, L., Zhang, Y., et al. (2014) Ultrasound Findings of Intraductal Papillary Neoplasm in Bile Duct and the Added Value of Contrast-Enhanced Ultrasound. Ultraschall in der MedizinEuropean Journal of Ultrasound, 36, 594-602.
https://doi.org/10.1055/s-0034-1366672
[10] Möller, K., Braden, B., Jenssen, C., Ignee, A., Cui, X.W., Yamashita, Y., et al. (2023) Intraductal Papillary Neoplasms of the Bile Ducts—What Can Be Seen with Ultrasound? Endoscopic Ultrasound, 12, 445-455.
https://doi.org/10.1097/eus.0000000000000040
[11] Li, J., Yu, Y., Zhu, L., Li, Y. and He, Q. (2020) Magnetic Resonance Imaging versus Computed Tomography for Biliary Tract Intraductal Papillary Mucinous Neoplasm (BT-IPMN): A Diagnostic Performance Analysis. Medical Science Monitor, 26, e920952-1.
https://doi.org/10.12659/msm.920952
[12] Youn, J.M., Hwang, S., Ahn, C., Moon, D., Ha, T., Song, G., et al. (2022) Clinicopathological Features and Long-Term Outcomes of Intraductal Papillary Neoplasms of the Bile Duct of the Liver: Single-Institution Experience with 146 Patients. Journal of Gastrointestinal Surgery, 26, 1394-1405.
https://doi.org/10.1007/s11605-022-05268-2
[13] Lee, S., Kim, M., Kim, S., Choi, D., Jang, K. and Park, Y.N. (2019) Intraductal Papillary Neoplasm of the Bile Duct: Assessment of Invasive Carcinoma and Long-Term Outcomes Using MRI. Journal of Hepatology, 70, 692-699.
https://doi.org/10.1016/j.jhep.2018.12.005
[14] Tringali, A., Milluzzo, S.M., Ardito, F., Laurenzi, A., Ettorre, G.M., Barbaro, B., et al. (2022) Peroral-Cholangioscopy to Plan Surgery for Protruding Biliary Lesions: Report of Four Cases. Therapeutic Advances in Gastrointestinal Endoscopy, 15.
https://doi.org/10.1177/26317745221139735
[15] Gordon-Weeks, A.N., Jones, K., Harriss, E., Smith, A. and Silva, M. (2016) Systematic Review and Meta-Analysis of Current Experience in Treating IPNB: Clinical and Pathological Correlates. Annals of Surgery, 263, 656-663.
https://doi.org/10.1097/sla.0000000000001426
[16] Wang, X. (2015) Biliary Tract Intraductal Papillary Mucinous Neoplasm: Report of 19 Cases. World Journal of Gastroenterology, 21, 4261-4267.
https://doi.org/10.3748/wjg.v21.i14.4261
[17] Kim, J.R., Lee, K., Kwon, W., Kim, E., Kim, S. and Jang, J. (2018) Comparison of the Clinicopathologic Characteristics of Intraductal Papillary Neoplasm of the Bile Duct According to Morphological and Anatomical Classifications. Journal of Korean Medical Science, 33, e266.
https://doi.org/10.3346/jkms.2018.33.e266
[18] Luvira, V., Pugkhem, A., Bhudhisawasdi, V., Pairojkul, C., Sathitkarnmanee, E., Luvira, V., et al. (2017) Long‐Term Outcome of Surgical Resection for Intraductal Papillary Neoplasm of the Bile Duct. Journal of Gastroenterology and Hepatology, 32, 527-533.
https://doi.org/10.1111/jgh.13481
[19] Mocchegiani, F., Vincenzi, P., Conte, G., Nicolini, D., Rossi, R., Cacciaguerra, A.B., et al. (2023) Intraductal Papillary Neoplasm of the Bile Duct: The New Frontier of Biliary Pathology. World Journal of Gastroenterology, 29, 5361-5373.
https://doi.org/10.3748/wjg.v29.i38.5361
[20] Inoue, M., Shimoda, E., Rikihisa, S. and Isohashi, F. (2025) A Case of Stereotactic Body Radiotherapy for Inoperable Intraductal Papillary Neoplasm of the Bile Duct. Cureus, 17, e80916.
https://doi.org/10.7759/cureus.80916
[21] Nakahata, A., Yamashita, Y., Yamazaki, H., Tsuda, I., Kawaji, Y., Ashida, R., et al. (2024) Intraductal Papillary Neoplasm of the Bile Duct Treated with Argon Plasma Coagulation via Endoscopic Ultrasound-Guided Choledochoduodenostomy. Internal Medicine, 63, 957-962.
https://doi.org/10.2169/internalmedicine.2083-23
[22] Wu, Y., Gu, W., Cheung, K.S., Yang, J., Zhang, X. and Jin, H. (2024) Cholangioscopy-Guided Laser Ablation for Intraductal Papillary Neoplasm of Bile Duct. Endoscopy, 56, E636-E637.
https://doi.org/10.1055/a-2357-2408
[23] Zhang, Y., Liang, Y., Liu, Y. and Feng, Y. (2022) Photodynamic Therapy for Hepatic Hilar Intraductal Papillary Neoplasm of the Bile Duct: A Case Report. VideoGIE, 7, 178-181.
https://doi.org/10.1016/j.vgie.2022.01.016